Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.4904 -0.0615 (-11.14%) 04/07/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.5248 +0.0344 (+7.01%) 19:30 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.4660
Day High
0.5483
Open 0.5301
Previous Close 0.5519 0.5519
Volume 4,412,500 4,412,500
Avg Vol 2,139,475 2,139,475
Stochastic %K 5.18% 5.18%
Weighted Alpha -76.48 -76.48
5-Day Change -0.1896 (-27.88%) -0.1896 (-27.88%)
52-Week Range 0.4660 - 1.9280 0.4660 - 1.9280
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,711
  • Shares Outstanding, K 186,104
  • Annual Sales, $ 98,430 K
  • Annual Income, $ -118,960 K
  • EBIT $ -146 M
  • EBITDA $ -141 M
  • 60-Month Beta 0.69
  • Price/Sales 1.14
  • Price/Cash Flow N/A
  • Price/Book 1.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.76
  • Most Recent Earnings $-0.15 on 03/12/25
  • Next Earnings Date 05/08/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 150.95% ( -104.17%)
  • Historical Volatility 79.93%
  • IV Percentile 75%
  • IV Rank 29.88%
  • IV High 485.47% on 02/06/25
  • IV Low 8.38% on 06/17/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 244
  • Volume Avg (30-Day) 637
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 40,949
  • Open Int (30-Day) 41,326

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 8
  • High Estimate -0.09
  • Low Estimate -0.21
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4660 +5.24%
on 04/07/25
Period Open: 0.8780
0.9639 -49.12%
on 03/17/25
-0.3876 (-44.15%)
since 03/07/25
3-Month
0.4660 +5.24%
on 04/07/25
Period Open: 1.1900
1.2400 -60.45%
on 01/08/25
-0.6996 (-58.79%)
since 01/07/25
52-Week
0.4660 +5.24%
on 04/07/25
Period Open: 1.3200
1.9280 -74.56%
on 05/13/24
-0.8296 (-62.85%)
since 04/05/24

Most Recent Stories

More News
Nektar: Q4 Earnings Snapshot

Nektar: Q4 Earnings Snapshot

NKTR : 0.4904 (-11.14%)
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

For Immediate ReleaseChicago, IL – February 3, 2025 – Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Amneal Pharmaceuticals AMRX, Dyne Therapeutics DYN, Nektar Therapeutics NKTR...

CORT : 74.65 (+0.27%)
DYN : 7.49 (-9.54%)
CRDL : 0.8500 (+4.94%)
AMRX : 7.21 (-2.30%)
NKTR : 0.4904 (-11.14%)
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

The biotech industry has declined since Donald Trump’s election victory. This was mainly because Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, to head the Health and Human Services, the agency...

CORT : 74.65 (+0.27%)
DYN : 7.49 (-9.54%)
CRDL : 0.8500 (+4.94%)
AMRX : 7.21 (-2.30%)
NKTR : 0.4904 (-11.14%)
Insider Sale: Chief R&D Officer of $NKTR (NKTR) Sells 7,785 Shares

Jonathan Zalevsky, the Chief R&D Officer of $NKTR ($NKTR), sold 7,785 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.1%...

NKTR : 0.4904 (-11.14%)
Nektar: Q3 Earnings Snapshot

Nektar: Q3 Earnings Snapshot

NKTR : 0.4904 (-11.14%)
Wall Street is Overlooking This Penny Stock, Says Analyst

This penny stock could surge up to 200%, according to one bull, who has high hopes for a pipeline drug ahead of trial data due out in 2025.

AAPL : 181.46 (-3.67%)
AMZN : 175.26 (+2.49%)
NKTR : 0.4904 (-11.14%)
Nektar: Q2 Earnings Snapshot

Nektar: Q2 Earnings Snapshot

NKTR : 0.4904 (-11.14%)
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...

NKTR : 0.4904 (-11.14%)
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...

NKTR : 0.4904 (-11.14%)
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...

NKTR : 0.4904 (-11.14%)

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 0.6194
2nd Resistance Point 0.5839
1st Resistance Point 0.5371
Last Price 0.4904
1st Support Level 0.4548
2nd Support Level 0.4193
3rd Support Level 0.3725

See More

52-Week High 1.9280
Fibonacci 61.8% 1.3695
Fibonacci 50% 1.1970
Fibonacci 38.2% 1.0245
Last Price 0.4904
52-Week Low 0.4660

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades